12–15 June 2022 • Berlin, Germany
Bayer AG Leverkusen/ Germany
12 June, 17:15: "Stimulating Soluble Guanylate Cyclase in Patients Following a Worsening HF Event"
AstraZeneca GmbH Wedel / Germany
13 June, 12:00: "Breaking the cycle of worsening metabolic, renal and cardiovascular disease step by step, our commitment to cardiometabolic medicines"
Novartis Pharma GmbH Nürnberg / Germany
14 June, 12:45: "New frontiers in lipid management: the advent of RNA-based therapies"